Cotton Mouton Diagnostics secures £500,000 investment from CPI Enterprises to advance its αBET testing technology, supporting sustainable pharmaceutical solutions.

Jul 31, 2025•5 months ago

Amount Raised

£500,000

CardiffBiotechnology

Investors

Cpi Enterprises

Description

Cotton Mouton Diagnostics has received a £500,000 investment from CPI Enterprises as part of the Innovate UK Catapult Associated Fund. This funding will help CMD further develop its innovative αBET benchtop instrument for endotoxin testing. The investment aligns with a UK Government strategy to support high growth potential companies. CMD's system offers a sustainable alternative to traditional testing methods with significant reductions in reagent consumption.

Company Information

Company

Cotton Mouton Diagnostics

Location

Cardiff, Wales, United Kingdom

About

Cotton Mouton Diagnostics (CMD) is a UK-based diagnostics technology company that specializes in innovative solutions for pharmaceutical testing. Founded in 2014, CMD initially focused on malaria diagnostics before pivoting to address broader safety testing in the pharmaceutical sector. Their flagship product, the αBET platform, offers a sustainable and efficient alternative to traditional endotoxin and pyrogen testing methods. CMD's technology significantly reduces reagent consumption and is designed to align with evolving regulatory trends in testing practices.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends